Chemotherapy-Induced Anemia Market

DelveInsight’s Chemotherapy-Induced Anemia Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, March 22, 2024 /EINPresswire.com/ --
Some of the key facts of the Chemotherapy-Induced Anemia Market Report:
The Chemotherapy-Induced Anemia market size was valued approximately USD 1 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
The number of individuals experiencing Chemotherapy Induced Anemia in the seven major markets (7MM) was approximated to be around 1.6 million cases in 2021.
Xu et al. (2016) found that 89.5% of patients with solid tumours experienced anaemia during chemotherapy (normocytic 85%, macrocytic 10%, microcytic 5%; normochromic 47%, hyperchromic 44%, hypochromic 9%)
According to Cancer Research UK's data from 2023, the incidence of head and neck cancer in the UK is anticipated to grow by 3% from 2023 to 2025. Concurrently, there is an expected 12% increase in deaths attributed to head and neck cancers during this period. These projections highlight the significance of addressing chemotherapy-induced anemia as a crucial aspect of cancer therapy.
Key Chemotherapy-Induced Anemia Companies: Fibrogen, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai Pharmaceutical, Hoffmann-La Roche, Amgen, Astellas Pharma, and others
Key Chemotherapy-Induced Anemia Therapies: Roxadustat, Desidustat, SEPO^®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others
The Chemotherapy-Induced Anemia epidemiology based on gender analyzed that no gender bias has been observed in case of Chemotherapy-Induced Anemia is seen
The Chemotherapy-Induced Anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy-Induced Anemia pipeline products will significantly revolutionize the Chemotherapy-Induced Anemia market dynamics.

Chemotherapy-Induced Anemia Overview
The primary and enduring blood-related condition among individuals with cancer is anemia. Chemotherapy-Induced Anaemia (CIA) occurs due to the infiltration of cancerous cells into healthy tissues, leading to blood loss, interference with erythropoiesis in the bone marrow, and functional iron deficiency caused by inflammation.

To Know in detail about the Chemotherapy-Induced Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy-Induced Anemia Market Forecast

Chemotherapy-Induced Anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chemotherapy-Induced Anemia Epidemiology Segmentation:
The Chemotherapy-Induced Anemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Chemotherapy-Induced Anemia
Prevalent Cases of Chemotherapy-Induced Anemia by severity
Gender-specific Prevalence of Chemotherapy-Induced Anemia
Diagnosed Cases of Episodic and Chronic Chemotherapy-Induced Anemia

Download the report to understand which factors are driving Chemotherapy-Induced Anemia epidemiology trends @ Chemotherapy-Induced Anemia Epidemiology Forecast

Chemotherapy-Induced Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Anemia market or expected to get launched during the study period. The analysis covers Chemotherapy-Induced Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy-Induced Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy-Induced Anemia Therapies and Key Companies
Roxadustat: Fibrogen
Desidustat: Zydus Cadila
SEPO^®: FibroGen
Epoetin alfa: Johnson & Johnson
peginesatide: Affymax
epoetin beta: Chugai Pharmaceutical
r-HuEPO: Hoffmann-La Roche
Aranesp: Amgen
Gilteritinib: Astellas Pharma

Scope of the Chemotherapy-Induced Anemia Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chemotherapy-Induced Anemia Companies: Fibrogen, Zydus Cadila, FibroGen, Johnson & Johnson, Affymax, Chugai Pharmaceutical, Hoffmann-La Roche, Amgen, Astellas Pharma, and others
Key Chemotherapy-Induced Anemia Therapies: Roxadustat, Desidustat, SEPO^®, Epoetin alfa, peginesatide, epoetin beta, r-HuEPO, Aranesp, Gilteritinib, and others
Chemotherapy-Induced Anemia Therapeutic Assessment: Chemotherapy-Induced Anemia current marketed and Chemotherapy-Induced Anemia emerging therapies
Chemotherapy-Induced Anemia Market Dynamics: Chemotherapy-Induced Anemia market drivers and Chemotherapy-Induced Anemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chemotherapy-Induced Anemia Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy-Induced Anemia Market Access and Reimbursement

To know more about Chemotherapy-Induced Anemia companies working in the treatment market, visit @ Chemotherapy-Induced Anemia Clinical Trials and Therapeutic Assessment

Table of Contents
1. Chemotherapy-Induced Anemia Market Report Introduction
2. Executive Summary for Chemotherapy-Induced Anemia
3. SWOT analysis of Chemotherapy-Induced Anemia
4. Chemotherapy-Induced Anemia Patient Share (%) Overview at a Glance
5. Chemotherapy-Induced Anemia Market Overview at a Glance
6. Chemotherapy-Induced Anemia Disease Background and Overview
7. Chemotherapy-Induced Anemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chemotherapy-Induced Anemia
9. Chemotherapy-Induced Anemia Current Treatment and Medical Practices
10. Chemotherapy-Induced Anemia Unmet Needs
11. Chemotherapy-Induced Anemia Emerging Therapies
12. Chemotherapy-Induced Anemia Market Outlook
13. Country-Wise Chemotherapy-Induced Anemia Market Analysis (2019–2032)
14. Chemotherapy-Induced Anemia Market Access and Reimbursement of Therapies
15. Chemotherapy-Induced Anemia Market Drivers
16. Chemotherapy-Induced Anemia Market Barriers
17. Chemotherapy-Induced Anemia Appendix
18. Chemotherapy-Induced Anemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.